Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers

Clinical and Translational Oncology

Volumn 15, Issue 7, 2013, Pages 503-508

  Conde, E ^a   Angulo, B ^a   Izquierdo, E ^a   Paz Ares, L ^b   Belda Iniesta, C ^a   Hidalgo, M ^a   Lopez Rios F ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

ALK; Biomarkers; EGFR; Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BEVACIZUMAB; CD56 ANTIGEN; CHROMOGRANIN; CRIZOTINIB; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PEMETREXED; PROTEIN P63; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1;

ADVANCED CANCER; ARTICLE; BRONCHUS BIOPSY; CANCER CLASSIFICATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 84879799050     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0983-z     Document Type: Article

References (71)

1. Travis WD, IASLC Staging Committee (2009) Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 54:3-11
2. Edwards SL, Roberts C, McKean ME et al (2000) Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non small cell category. J Clin Pathol 53:537-540
3. Chuang MT, Marchevsky A, Teirstein AS et al (1984) Diagnosis of lung cancer by fibreoptic bronchoscopy: problems in the histological classification of non-small cell carcinomas. Thorax 39:175-178
4. Thomas JS, Lamb D, Ashcroft T et al (1993) How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. Thorax 48:1135-1139
5. Abratt RP, Lee JS, Han JY et al (2006) Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer. J Thorac Oncol 1:135-140
6. Pfister DG, Johnson DH, Azzoli CG, American Society of Clinical Oncology et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353
7. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (2004) Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization (WHO) Classification of Tumours. IARC Press, Lyon
8. Travis WD, Brambilla E, Noguchi M et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285
9. Kerr KM (2012) Personalized medicine for lung cancer: new challenges for pathology. Histopathology 60:531-546
10. Langer CJ, Besse B, Gualberto A et al (2010) The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 28:5311-5320
11. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
12. Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
13. Pao W, Miller V, Zakowski M et al (2003) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311
14. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703
15. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551
16. De Marinis F, Pereira JR, Fossella F et al (2008) Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 3:30-36
17. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542-2550
18. Kubota K, Niho S, Enatsu S et al (2009) Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol 4:1530-1536
19. Hirsch FR, Wynes MW, Gandara DR et al (2010) The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res 16:4909-4911
20. Dacic S (2011) Lung carcinoma morphology or mutational profile: that is the question. Arch Pathol Lab Med 135:1242-1243
21. Rekhtman N, Paik PK, Arcila ME et al (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18:1167-1176
22. Conde E, Angulo B, Tang M et al (2006) Molecular context of the epidermal growth factor receptor mutations: evidence for the activation of mTOR/S6 K signaling. Clin Cancer Res 12:710-717
23. Wilkerson MD, Yin X, Walter V et al (2012) Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomalinstability, and methylation. PLoS One 7:e36530
24. Travis WD (2012) Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 1:S18-S30
25. Leslie KO, Wick MR (2011) Practical pulmonary pathology. A diagnostic approach. Churchill Livingstone, Philadelphia
26. Au NH, Gown AM, Cheang M et al (2004) P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 12:240-247
27. Warth A, Muley T, Herpel E et al (2012) Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 61:1017-1025
28. Conde E, Angulo B, Redondo P et al (2010) The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One 5:e12209
29. Angulo B, Suarez-Gauthier A, Lopez-Rios F et al (2008) Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 214:347-356
30. Monica V, Ceppi P, Righi L et al (2009) Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 22:709-717
31. Mukhopadhyay S, Katzenstein AL (2011) Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 35:15-25
32. Pelosi G, Rossi G, Bianchi F et al (2011) Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 6:1039-1049
33. Terry J, Leung S, Laskin J et al (2010) Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 34:1805-1811
34. Sterlacci W, Savic S, Schmid T et al (2012) Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol 137:946-956
35. Thunnissen E, Kerr KM, Herth FJ et al (2012) The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 76:1-18
36. Bishop JA, Teruya-Feldstein J, Westra WH et al (2012) p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25:405-415
37. Pelosi G, Fabbri A, Bianchi F et al (2012) ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 7:281-290
38. Nonaka D (2012) A study of ΔNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 36:895-899
39. Mino-Kenudson M, Mark EJ (2011) Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med 135:655-664
40. Garrido P, de Castro J, Concha A et al (2012) Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol 14:338-349
41. Angulo B, Conde E, Suárez-Gauthier A et al (2012) A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing real-time PCR and immunohistochemistry. PLoS One 7:e43842
42. Conde E, Angulo B, Izquierdo E et al (2012) The ALK translocation in advanced NSCLCs: pre-approval testing experience at a Single Cancer Center. Histopathology. doi: 10.1111/his.12037
43. Bergethon K, Shaw AT, Ou SH et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 3:863-870
44. Atherly AJ, Camidge DR (2012) The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 106:1100-1106
45. Angulo B, Conde E, Martínez R et al (2011) Analytic performance of a novel real-time PCR method for the detection of mutations in EGFR in formalin-fixed paraffin-embedded tissue (FFPET) samples of lung cancer. J Thorac Oncol 6:S1061
46. Yatabe Y, Kosaka T, Takahashi T et al (2005) EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29:633-639
47. Motoi N, Szoke J, Riely GJ et al (2008) Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expressionanalysis. Am J Surg Pathol 32:810-827
48. Yousem SA, Nikiforova M, Nikiforov Y (2008) The histopathology of BRAF-V600E-mutated lung adenocarcinoma. Am J Surg Pathol 32:1317-1321
49. Yoshida A, Tsuta K, Nakamura H et al (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35:1226-1234
50. Thunnissen E, Bubendorf L, Dietel M et al (2012) EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 461:245-257
51. Cobas DNA Sample Preparation Kit CE-IVD package insert 2011
52. Cobas EGFR Mutation Kit CE-IVD package insert 2011
53. Chen ZY, Zhong WZ, Zhang XC et al (2012) EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 17:978-985
54. Kim H, Xu X, Yoo S-B et al (2013) Discordance between anaplastic lymphoma kinase status in primary non-small cell lung cancer and their corresponding metastases. Histopathology 62:305-314
55. Kelly RJ, Carter CA, Giaccone G (2012) HER2 Mutations in Non-Small-Cell Lung Cancer Can Be Continually Targeted. J Clin Oncol 30:3318-3319
56. Doebele RC, Pilling AB, Aisner DL et al (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18:1472-1482
57. Wallander ML, Geiersbach KB, Tripp SR et al (2012) Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 136:796-803
58. Pao W, Ladanyi M (2007) Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13:4954-4955
59. Oxnard GR, Jänne PA (2012) KRAS wild-type lung cancer: a moving target in an era of genotype migration. J Clin Oncol 30:3322-3324
60. Arcila ME, Chaft JE, Nafa K et al (2012) Prevalence, clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 18:4910-4918
61. Paik PK, Arcila ME, Fara M et al (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046-2051
62. Gautschi O, Pauli C, Strobel K et al (2012) A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 7:e23-e24
63. Ou SH, Kwak EL, Siwak-Tapp C et al (2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6:942-946
64. Spigel DR, Ervin TJ, Ramlau R et al (2010) Randomized multicenter double blind placebo controlled phase II study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. Ann Oncol 21 (abstr LBA5146)
65. Takeuchi K, Soda M, Togashi Y et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381
66. Eberhard DA, Giaccone G, Johnson BE et al (2008) Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26:983-999
67. Pirker R, Herth FJ, Kerr KM et al (2010) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5:1706-1713
68. Gold KA, Wistuba II, Kim ES (2012) New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res 18:3002-3007
69. Weiss J, Sos ML, Seidel D et al (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93
70. Hammerman PS, Sos ML, Ramos AH et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78-89
71. Janku F, Tsimberidou AM, Garrido-Laguna I et al (2011) PIK3CA mutations in patients with advanced cancers treated with PI3 K/AKT/mTOR axis inhibitor. Mol Cancer Ther 10:558-565 Investigaciones Sanitarias